News Search Year - Any - 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2009 2008 Archive September 17, 2020 Deciphera Presents Data from Rebastinib, its TIE2 Inhibitor Program, at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 Archive August 17, 2020 Deciphera Announces Publication of QINLOCK™ (ripretinib) Phase 1 Study Results in Patients with Gastrointestinal Stromal Tumor in Journal of Clinical Oncology Archive August 6, 2020 Deciphera Pharmaceuticals, Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference Archive August 4, 2020 Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2020 Financial Results Archive July 29, 2020 Deciphera Pharmaceuticals, Inc. to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 4, 2020 Archive July 20, 2020 China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor Archive July 14, 2020 Deciphera Announces Australian Therapeutic Goods Administration’s Approval of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor Archive July 2, 2020 Deciphera Announces Presentation of Analysis of Crossover Population from the INVICTUS Phase 3 Study of QINLOCK™ (ripretinib) in Patients with Fourth-Line Advanced GIST Archive June 22, 2020 Deciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor Archive June 11, 2020 Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Forum
Archive September 17, 2020 Deciphera Presents Data from Rebastinib, its TIE2 Inhibitor Program, at the European Society for Medical Oncology (ESMO) Virtual Congress 2020
Archive August 17, 2020 Deciphera Announces Publication of QINLOCK™ (ripretinib) Phase 1 Study Results in Patients with Gastrointestinal Stromal Tumor in Journal of Clinical Oncology
Archive August 6, 2020 Deciphera Pharmaceuticals, Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference
Archive August 4, 2020 Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2020 Financial Results
Archive July 29, 2020 Deciphera Pharmaceuticals, Inc. to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 4, 2020
Archive July 20, 2020 China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor
Archive July 14, 2020 Deciphera Announces Australian Therapeutic Goods Administration’s Approval of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Archive July 2, 2020 Deciphera Announces Presentation of Analysis of Crossover Population from the INVICTUS Phase 3 Study of QINLOCK™ (ripretinib) in Patients with Fourth-Line Advanced GIST
Archive June 22, 2020 Deciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Archive June 11, 2020 Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Forum
